Anti-tumor Effects of Cyclolinopeptide on Giant-cell Tumor of the Bone

Area of Science:

• Oncology
• Bone Biology
• Molecular Biology

Background:

• Giant-cell tumors of the bone (GCTB) are characterized by aggressive osteoclastogenesis.
• Receptor activator of nuclear factor-κB ligand (RANKL) signaling plays a critical role in GCTB development.
• Novel therapeutic strategies targeting RANKL are needed for GCTB treatment.

Purpose of the Study:

• To investigate the in vitro antitumor effects of cyclolinopeptide (CL) on GCTB cells.
• To evaluate the impact of CL on RANKL signaling pathways in GCTB.
• To assess the efficacy of CL in inhibiting GCTB cell proliferation and survival.

Main Methods:

• GCTB cell lines were established for experimental use.
• Cell proliferation was assessed using water-soluble tetrazolium salt-8, cell cycle, and EdU assays.
• Real-time polymerase chain reaction was employed to measure RANKL and RUNX2 expression levels before and after CL treatment.

Main Results:

• CL significantly inhibited GCTB cell growth in a dose-dependent manner (p<0.05).
• CL treatment led to an increased proportion of cells in the G0/G1 phase and a decreased ratio of EdU-positive cells (p<0.05).
• Expression levels of RANKL and RUNX2 were significantly reduced following CL administration (p<0.05).

Conclusions:

• Cyclolinopeptide (CL) exhibits significant antitumor activity against GCTB cells in vitro.
• CL effectively suppresses key signaling pathways, including RANKL and RUNX2, involved in GCTB progression.
• CL represents a potential therapeutic agent for the treatment of giant-cell tumors of the bone.